Anthem Biosciences Limited (NSE: ANTHEM) and Sai Life Sciences Limited (NSE: SAILIFE) are both listed in the Pharmaceutical CDMO and CRO Services industry. Anthem Biosciences has a market capitalisation of ₹47,055 Cr and Sai Life Sciences ₹32,761 Cr, as of 9 Nov 2026. Their P/E ratios are 80.1 and 93.9 respectively. Return on equity is 19.45% for Anthem Biosciences and 15.13% for Sai Life Sciences. Over one year, Anthem Biosciences's share price is up 36.4% and Sai Life Sciences's is up 99.0%.
| Metric | Anthem Biosciences | Sai Life Sciences |
|---|---|---|
| NSE Symbol | ANTHEM | SAILIFE |
| BSE Code | 544449 | 544306 |
| Share Price | ₹959.00 | ₹1,836.00 |
| Market Cap | ₹47,055 Cr | ₹32,761 Cr |
| P/E Ratio | 80.1 | 93.9 |
| Return on Equity | 19.45% | 15.13% |
| Return on Assets | 14.20% | 8.57% |
| Dividend Yield | 0.24% | — |
| Beta (1Y) | 0.56 | 0.4 |
| 1-Year Price Change | +36.4% | +99.0% |
| 3-Month Price Change | +12.4% | +28.7% |
| 52-Week Range | ₹579.15 – ₹989.10 | ₹783.85 – ₹1,897.30 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹594 Cr | ₹659 Cr |
| Quarterly Net Profit | ₹211 Cr | ₹98 Cr |
| Net Margin | 35.6% | 14.9% |
| EPS (Basic, Quarter) | ₹3.75 | ₹4.63 |
| Results Basis | consolidated | consolidated |
| Headquarters | Bengaluru, Karnataka | Hyderabad, Telangana |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Anthem Biosciences Limited operates as a contract research, development, and manufacturing organization in India, rest of Asia, North America, Europe, and internationally. It operates in two segments: Contract Manufacturing, Development & Discovery Services; and Speciality Ingredients. The company offers contract research development and manufacturing services, such as end-to-end services across the new chemical entity and new biological entity lifecycles, as well as engages in contract research, development, and manufacturing of development batches of molecules used for clinical trials up to …
Sai Life Sciences Limited operates as a contract research, development, and manufacturing organization (CRDMO) in India and internationally. It provides medicinal chemistry, pharmacokinetics, manufacturing, and contract development services. The company was formerly known as SAI Advantium Pharma Limited and changed its name to Sai Life Sciences Limited in July 2006. Sai Life Sciences Limited was incorporated in 1999 and is based in Hyderabad, India.
Anthem Biosciences has a market capitalisation of ₹47,055 Cr, against ₹32,761 Cr for Sai Life Sciences as of 9 Nov 2026, about 1.4 times the size by market cap.
Anthem Biosciences has a P/E of 80.1 and Sai Life Sciences a P/E of 93.9 as of 9 Nov 2026.
Anthem Biosciences has a return on equity of 19.45% and Sai Life Sciences 15.13%.
Anthem Biosciences's share price is up 36.4% over one year and Sai Life Sciences's is up 99.0%.
Anthem Biosciences reported revenue of ₹594 Cr and net profit of ₹211 Cr for Q2 FY27. Sai Life Sciences reported revenue of ₹659 Cr and net profit of ₹98 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.